Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment

This 2024 study by Jabbour et al. evaluated the clinical outcomes of patients with type 2 diabetes mellitus (T2DM) who switched from existing GLP-1 receptor agonists to a 5 mg dose of tirzepatide over a 12-week period. The study aimed to assess changes in glycemic control, body weight, and tolerability